Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adial Pharmaceuticals Inc (NQ: ADIL )

1.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adial Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application. 
Via Benzinga
Exposures Product Safety
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
ADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024
Adial Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal... 
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4
Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results... 
Via Benzinga
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Is Serve Robotics (SERV) Stock Down Today?
Serve Robotics stock is down on Tuesday after the company revealed the pricing of warrants for SERV shares in a private placement. 
Via InvestorPlace
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Jaguar Health stock is down on Tuesday as JAGX investors react to failed results from a Phase 3 clinical trial of crofelemer. 
Via InvestorPlace
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?
Adial Pharmaceuticals stock is up with heavy trading of ADIL after providing investors with an update on its AD04 clinical trial. 
Via InvestorPlace
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights for... 
Via Benzinga
ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023
ADIL stock results show that Adial Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching... 
Via Benzinga
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals starts dosing in pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. Topline results in early Q4 2024. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024
ADIL stock results show that Adial Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Adial Pharmaceuticals' genetic diagnostic patent, expanding treatment for alcohol and drug dependencies. CEO highlights the significance. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.